Evaluating new imaging technology for cancer radiation therapy
Official title: A Feasibility Study of a Novel Cone-Beam CT Approach for Image Guided Radiotherapy in Cancer Patients
Run by Varian, a Siemens Healthineers Company · NCT06681233 · Data updated 2026-11-12
This study is testing a new imaging technology for cancer radiation therapy to see if it can provide better pictures than the standard method, helping patients get more effective treatment.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | Varian, a Siemens Healthineers Company Industry-sponsored |
| Drugs / interventions | radiation |
| Locations | 4 sites (Columbus, Ohio and 3 other locations) |
| Status | Recruiting |
| Started | February 19, 2025 |
| Main results expected | August 2026 |
| Study ends | September 2026 |
| Registry record updated | March 13, 2026 |
| Trial ID | NCT06681233 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 and older who are undergoing radiation therapy for head and neck, thoracic, liver, breast, genitourinary, or gastrointestinal cancers.
✕Probably not a fit
Patients with a poor performance status, limited life expectancy, or those unable to provide informed consent may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the feasibility of a new imaging technology called HyperSight, developed by Varian Medical Systems, for use in radiation therapy for various cancers. HyperSight is designed to improve image quality compared to conventional cone beam computed tomography (CBCT), which is commonly used for patient alignment during treatment. The study will compare the imaging capabilities of HyperSight CBCT with traditional CBCT to determine its effectiveness in enhancing the radiation therapy workflow. Patients receiving radiation therapy for specific malignancies will be included in the study.
Why it matters
Potential benefit: If successful, this technology could lead to improved imaging quality, enhancing the precision of radiation therapy for cancer patients.
How similar studies have gone: While this approach is innovative, it builds on existing imaging technologies, and similar studies have shown promise in improving imaging quality in radiation therapy.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patient age ≥ 18 2. Patient is receiving radiation therapy for head and neck, thorax, liver, breast, genitourinary, or gastrointestinal malignancies 3. A CBCT acquisition for localization is standard of care for the radiation therapy treatment plan being delivered Exclusion Criteria: 1. Patient has ECOG Performance Status ≥3. 2. Patient is wheelchair bound. 3. Patient has a life expectancy \<3 months. 4. Patient is unwilling or unable to provide informed consent to participate in the study. 5. Patient is pregnant or has plans for pregnancy during the period of treatment. 6. Patient is part of a vulnerable population (per ISO 14155:2020, "individuals who are unable to fully understand all aspects of the investigation that are relevant to the decision to participate, or who could be manipulated or unduly influenced as a result of a compromised position, expectation of benefits or fear of retaliatory response"). This includes prisoners.
Where it's running
-
James Outpatient Center
Columbus, Ohio, United States Recruiting -
Ohio State University, Brain and Spine Hospital
Columbus, Ohio, United States Recruiting -
The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Columbus, Ohio, United States Recruiting -
Stefanie Spielman Comprehensive Breast Center
Columbus, Ohio, United States Recruiting
Study contacts
- Study coordinator: Sean Davidson
- Email: sean.davidson@varian.com
- Phone: 437-991-8294
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
PD-L1-targeted PET probe to map PD-L1 in solid tumors
A PET tracer called 18F-F-PDL1-3 is being tested to see if it can detect PD-L1 expression in primary and metastatic tumors to help guide personalized treatment.
-
Precision navigation to boost cancer screening participation in high-risk communities
This study tests whether a personalized navigation program helps adults aged 45–74 in Chinese communities who are at high risk for several cancers to complete recommended free cancer screenings.
-
AI language tools to help tumor care teams write MDT reports
We will test whether AI language tools can help junior cancer doctors write MDT diagnosis and treatment reports more accurately and faster.
-
Riluzole to prevent thinking and memory problems during chemotherapy
This pilot trial tests whether riluzole can prevent thinking and memory problems in adults with cancer receiving anthracycline- or platinum-based chemotherapy.
-
Biomarker-guided donor CAR-NK therapy targeting one or two tumor antigens for advanced solid tumors
This treatment tries donor-derived CAR-NK cells that target one or two tumor antigens for adults with advanced solid tumors such as breast, NSCLC, colorectal, and recurrent prostate cancer.
-
SL-28 for Advanced Solid Tumours
A new allogeneic cell therapy called SL-28 is being tested in adults with advanced solid tumors to see if it is safe and can help shrink tumors.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.